Human Stem Cells Institute

The Human Stem Cells Institute is a Russian biotechnology company. It was founded in 2003. It is engaged in scientific research, development of innovative drugs and high-tech services in the field of regenerative medicine, medical genetics, gene therapy, bioinsurance and biopharmaceuticals. It independently promotes his own developments in the market.
Human Stem Cells Institute stock price chart
-33%
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Human Stem Cells Institute balance sheet

Report period2017 2018 2019 2020 2021 Q2 22
End date of the reporting period
Capitalization, ₽
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Human Stem Cells Institute cash flows

Report period2017 2018 2019 2020 2021 Q2 22 TTM
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
OIBDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Human Stem Cells Institute multipliers

Report period2017 2018 2019 2020 2021 Q2 22 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/OIBDA
EV/EBITDA
EV/OIBDA

Human Stem Cells Institute profitability

Report period2017 2018 2019 2020 2021 Q2 22 TTM
ROA
ROE
ROS
EBITDA Margin
Operating margin
Human Stem Cells Institute assets
Human Stem Cells Institute cash flows
Human Stem Cells Institute dividends
0%

Human Stem Cells Institute shares

TickerNameTypeNominal valueISINPrice
ISKJ:RMHuman Stem Cells InstituteCommon shareRUB 0.1RU000A0JNAB6RUB 57.82

Human Stem Cells Institute bonds

NameIssue sizePriceYield
ISKJ BO-01300,000 pcs.RUB 97.229.88%
Share capital structure of Human Stem Cells Institute
Human Stem Cells Institute news
21.09.2022
HSCI is not planning to pay dividends this year and next year; it may consider the issue in 2024, the company's chairman, Artur Isaev, told Finam Online. "The dividend policy is simple - as long as we have expenses and investments our more than income, and it is profitable for us to invest, we will try to do so," he explained.
Source: {source} pictogram finam.ru
01.09.2022
Developer of Russian coronavirus vaccine Betuvax company, part of HSCI, completed Phase I-II clinical trials, which confirmed the efficacy and safety of the drug. Vaccine was tested at three clinical centers in St. Petersburg and Perm with the participation of 116 volunteers who had not previously had covid and had not been vaccinated.
Source: {source} pictogram betuvax.ru
30.08.2022
Human Stem Cell Institute's IFRS net income for 6 months of 2022 was ₽29.925 million, up 15.8% from ₽25.845 million in the previous year. Revenue decreased 6.6% to ₽519.89 million versus ₽556.75 million a year earlier.
19.08.2022
HSCI completed a private placement of additional common shares in favor of IMCB at ₽80 per share. 7,645,951 shares or 61.17% of the issue were placed
General information
Company nameHuman Stem Cells Institute
Tags#biotechnology, #pharmacy
SectorHealth Care / Health Care Equipment & Services / Health Care Providers & Services / Health Care Services
Business addressRF, g. Moskva
Mailing address117036, g. Moskva, prospekt 60-letiya Oktyabrya, d. 10A, etazh 3, pom. 24
CEOMasyuk Sergey Vladimirovich
Phone+7 (495) 646-80-76
Websitehsci.ru
Information disclosuree-disclosure.ru